ES2183170T3 - Composicion farmaceutica estable del factor bdnf. - Google Patents

Composicion farmaceutica estable del factor bdnf.

Info

Publication number
ES2183170T3
ES2183170T3 ES97922156T ES97922156T ES2183170T3 ES 2183170 T3 ES2183170 T3 ES 2183170T3 ES 97922156 T ES97922156 T ES 97922156T ES 97922156 T ES97922156 T ES 97922156T ES 2183170 T3 ES2183170 T3 ES 2183170T3
Authority
ES
Spain
Prior art keywords
bdnf
pct
pharmaceutical composition
stable pharmaceutical
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97922156T
Other languages
English (en)
Inventor
Kaatsumi Tanaka
Masashi Kumano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Regeneron Pharmaceuticals Inc
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Regeneron Pharmaceuticals Inc filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2183170T3 publication Critical patent/ES2183170T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA ESTABLE DEL FACTOR NEUROTROPICO DERIVADO DEL CEREBRO (BDNF) BAJO LA FORMA DE UNA SOLUCION ACUOSA O DE UNA SOLUCION LIOFILIZADA, APROPIADA PARA UNA CONSERVACION DE LARGA DURACION, QUE CONTIENE UN COMPONENTE TENSIOACTIVO, EN PARTICULAR UN ELEMENTO TENSIOACTIVO NO IONICO (POR EJEMPLO, TWEEN 80) A RAZON DE 0,001 AL 10 %, DE MANERA QUE LA POLIMERIZACION Y LA DESNATURALIZACION DE ESTE FACTOR BDNF SEAN INHIBIDAS Y LAS ACTIVIDADES BIOLOGICAS DE ESTE FACTOR BDNF SEAN MANTENIDAS DURANTE UN LARGO PERIODO. ESTA COMPOSICION LIOFILIZADA PUEDE HACERSE MAS ESTABLE MEDIANTE LA ADICION DE UN ALCOHOL DE AZUCAR (POR EJEMPLO, MANNITOL) Y/O DE UN AMINOACIDO (POR EJEMPLO, LA GLICINA).
ES97922156T 1996-05-27 1997-05-26 Composicion farmaceutica estable del factor bdnf. Expired - Lifetime ES2183170T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8156070A JPH10212241A (ja) 1996-05-27 1996-05-27 Ｂｄｎｆを安定に含有する製剤

Publications (1)

Publication Number Publication Date
ES2183170T3 true ES2183170T3 (es) 2003-03-16

Family

ID=15619654

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97922156T Expired - Lifetime ES2183170T3 (es) 1996-05-27 1997-05-26 Composicion farmaceutica estable del factor bdnf.

Country Status (11)

Country Link
US (1) US6077829A (es)
EP (1) EP0910399B1 (es)
JP (1) JPH10212241A (es)
AT (1) ATE223728T1 (es)
AU (1) AU715571B2 (es)
CA (1) CA2256410C (es)
DE (1) DE69715414T2 (es)
DK (1) DK0910399T3 (es)
ES (1) ES2183170T3 (es)
PT (1) PT910399E (es)
WO (1) WO1997045135A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU5105100A (en) * 1999-06-03 2000-12-28 Eisai Co. Ltd. Crystals of carbapenem derivatives and pharmaceutical preparations for injection
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002096356A2 (en) * 2001-05-25 2002-12-05 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20040096828A1 (en) * 2002-01-04 2004-05-20 Lu Dyung Aina M Cytoskeleton-associated proteins
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
CA2513226A1 (en) * 2003-01-13 2004-07-29 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
MX2007015292A (es) 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
CN103301475B (zh) 2005-12-28 2016-08-03 斯克里普斯研究所 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
IT1396607B1 (it) 2009-11-16 2012-12-14 Hmfra Hungary Ltd Liability Company Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso.
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
ES2694592T3 (es) 2012-03-15 2018-12-21 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
JP2021019532A (ja) * 2019-07-26 2021-02-18 花王株式会社 血液脳関門保護剤
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
AU6909091A (en) * 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol

Also Published As

Publication number Publication date
ATE223728T1 (de) 2002-09-15
DE69715414T2 (de) 2003-05-15
CA2256410C (en) 2007-02-27
AU2792397A (en) 1998-01-05
US6077829A (en) 2000-06-20
EP0910399A1 (en) 1999-04-28
CA2256410A1 (en) 1997-12-04
PT910399E (pt) 2002-11-29
AU715571B2 (en) 2000-02-03
WO1997045135A1 (en) 1997-12-04
DE69715414D1 (de) 2002-10-17
DK0910399T3 (da) 2003-01-06
EP0910399B1 (en) 2002-09-11
JPH10212241A (ja) 1998-08-11

Similar Documents

Publication Publication Date Title
DK0910399T3 (da) Stabilt farmaceutisk BDNF-præparat
ES2563677T3 (es) Composiciones de combinaciones de Neisseria
SE9201073D0 (sv) Protein formulation
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
BR0004884A (pt) Composições acaricidas
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
ES2102813T3 (es) Composiciones farmaceuticas y dermocosmeticas que contienen calostro equino.
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
BR0205595A (pt) Composição para a tintura de oxidação das fibras queratìnicas, composição pronta para o uso para a tintura de oxidação das fibras queratìnicas, processos de tintura das fibras queratìnicas e dispositivos com vários compartimentos ou 'kit' para a tintura das fibras queratìnicas
ES2187820T3 (es) Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.
DK0641216T3 (da) Farmaceutisk præparat indeholdende IL-6
DE60009926D1 (de) Stabilisierung von gefriergetrocknetem kuchen
BR0107544A (pt) Composição de promoção de secreção de bile
ATE303816T1 (de) Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
DK1074264T3 (da) Inhibitorer for neovaskularisering
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
BR0208879A (pt) Artigo
SG153894G (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
ATE306914T1 (de) Wässerige lösung zur behandlung von enteroclysis bei hepatischer enzephalopathie
DE69936190D1 (de) Verwendung von itakonsäure zur regulierung des glykolytischen stoffwechsels
YU44292A (sh) Superaktivni analozi faktora oslobadjanja hormona rasta